{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:14:40Z","timestamp":1791918880345,"version":"4.3.4"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["YO:17K08324, SS:16K21501"],"award-info":[{"award-number":["YO:17K08324, SS:16K21501"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01045","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T13:17:47Z","timestamp":1568726267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":71,"title":["Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects"],"prefix":"10.3389","volume":"10","author":[{"given":"Yukihiro","family":"Ohno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Kunisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2008.08.004","article-title":"Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial","volume":"107","author":"Akhondzadeh","year":"2009","journal-title":"Schizophr. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-2007-979623","article-title":"Psychopharmacology of central serotonergic systems","volume":"28","author":"Baumgarten","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/sj.npp.1301294","article-title":"Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors","volume":"32","author":"Bonsi","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1017\/S1041610218001229","article-title":"Prescribing of psychotropic drugs and indicators for use in residential aged care and residents with dementia","volume":"31","author":"Brimelow","year":"2019","journal-title":"Int. Psychogeriatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0014-2999(01)01399-1","article-title":"Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine","volume":"430","author":"Bymaster","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/BF00169040","article-title":"Dopaminergic regulation of striatal cholinergic interneurons: an in vivo microdialysis study","volume":"342","author":"Damsma","year":"1990","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/157488610791698325","article-title":"Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects","volume":"5","author":"DeBattista","year":"2010","journal-title":"Curr. Drug Saf."},{"key":"B11","first-page":"775","article-title":"Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes","volume":"277","author":"DeBoer","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/diagnostics5040564","article-title":"Prevalence of Behavioural and Psychological Symptoms of Dementia in Individuals with Learning Disabilities","volume":"5","author":"Devshi","year":"2015","journal-title":"Diagnostics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4088\/PCC.v07n0602","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1021\/jm049632c","article-title":"Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents","volume":"48","author":"Fern\u00e1ndez","year":"2005","journal-title":"J. Med. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/0166-2236(91)90117-D","article-title":"Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence","volume":"14","author":"Fibiger","year":"1991","journal-title":"Trends Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00004714-199710000-00007","article-title":"Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses","volume":"17","author":"Gill","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hup.750","article-title":"A systematic review of the serotonergic effects of Mirtazapine in humans: implications for its dual action status","volume":"21","author":"Gillman","year":"2006","journal-title":"Hum. Psychopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/sj.mp.4000801","article-title":"Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly","volume":"6","author":"Govoni","year":"2001","journal-title":"Mol. Psychiatry"},{"key":"B19","first-page":"15","article-title":"Neurological complications of psychiatric drugs: clinical features and management","volume-title":"Hum. Psychopharmacol.","author":"Haddad","year":"2008"},{"key":"B20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neulet.2009.03.001","article-title":"Therapeutic potential of \u03b12 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders","volume":"454","author":"Imaki","year":"2009","journal-title":"Neurosci. Lett."},{"key":"B21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-019-09200-8","article-title":"Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis","volume-title":"J. Neurol","author":"Jin","year":"2019"},{"key":"B23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1017\/S1041610218000534","article-title":"Management of behavioral and psychological symptoms in people with Alzheimer\u2019s disease: an international Delphi consensus","volume":"31","author":"Kales","year":"2019","journal-title":"Int. Psychogeriatr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","article-title":"Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia","volume":"52","author":"Kapur","year":"2001","journal-title":"Ann. Rev. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.745","article-title":"Pharmacological management of behavioural and psychological disturbance in dementia","volume":"21","author":"Kozman","year":"2006","journal-title":"Hum. Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bmj.38125.465579.55","article-title":"Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review","volume":"329","author":"Lee","year":"2004","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00213-002-1121-3","article-title":"Postsynaptic 5-HT1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat","volume":"163","author":"Mignon","year":"2002","journal-title":"Psychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pbb.2016.12.015","article-title":"Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats","volume":"153","author":"Mombereau","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B31","first-page":"207","article-title":"Serotonergic involvement in haloperidol-induced catalepsy","volume":"265","author":"Neal-Beliveau","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1017\/S1041610203009098","article-title":"Behavioral symptoms in vascular cognitive impairment and vascular dementia","volume":"15","author":"O\u2019Brien","year":"2003","journal-title":"Int. Psychogeriatr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/002383099200500108","article-title":"Incontinence and troublesome behaviors predict institutionalization in dementia","volume":"5","author":"O\u2019Donnell","year":"1992","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"B34","first-page":"213","article-title":"Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone","volume":"49","author":"Ohno","year":"1997","journal-title":"Pol. J. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.neuropharm.2008.06.005","article-title":"Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens","volume":"55","author":"Ohno","year":"2008","journal-title":"Neuropharmacology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.pnpbp.2008.04.005","article-title":"Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test","volume":"32","author":"Ohno","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1254\/jphs.08313FP","article-title":"Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice","volume":"109","author":"Ohno","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.08.019","article-title":"Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors","volume":"60","author":"Ohno","year":"2011","journal-title":"Neuropharmacology"},{"key":"B39","first-page":"323","article-title":"\u201cManagement of cognitive impairments in schizophrenia: the therapeutic role of 5-HT receptors,\u201d","volume-title":"Schizophrenia Research: Recent Advances","author":"Ohno","year":"2012"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1248\/bpb.b13-00310","article-title":"Pathophysiological roles of serotonergic system in regulating extrapyramidal motor function","volume":"36","author":"Ohno","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"B41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pneurobio.2015.09.005","article-title":"New insight into the therapeutic role of the serotonergic system in Parkinson\u2019s disease","volume":"134","author":"Ohno","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"B42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/B978-0-12-800050-2.00018-8","article-title":"\u201cSerotonin receptors as the therapeutic target for central nervous system disorders,\u201d","volume-title":"Serotonin: The mediator that spans evolution","author":"Ohno","year":"2019"},{"key":"B43","article-title":"\u201cWorld alzheimer report 2015 \u2014 The global impact of dementia: an analysis of prevalence, incidence, cost and trends,\u201d (Alzheimer\u2019s Disease International, London)","author":"Prince","year":"2015"},{"key":"B44","first-page":"15","article-title":"D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET","volume":"60","author":"Remington","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.ypmed.2012.12.025","article-title":"Behavioural and psychological symptoms of dementia, cognitive impairment and caregiver burden in patients with dementia","volume":"57","author":"Rosdinom","year":"2013","journal-title":"Prev. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/S0024-3205(01)01055-4","article-title":"Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism","volume":"68","author":"Salamone","year":"2001","journal-title":"Life Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson\u2019s disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2165\/00023210-200418130-00001","article-title":"Combination therapy in Alzheimer\u2019s disease: a review of current evidence","volume":"18","author":"Schmitt","year":"2004","journal-title":"CNS Drugs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.pnpbp.2010.04.005","article-title":"Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders","volume":"34","author":"Shimizu","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2174\/18715273113129990088","article-title":"Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions","volume":"12","author":"Shimizu","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pnpbp.2013.06.016","article-title":"5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms","volume":"46","author":"Shimizu","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jphs.2015.03.004","article-title":"Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice","volume":"127","author":"Shimizu","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0028-3908(94)00146-J","article-title":"Effects of 5-HT3 receptor antagonists on neuroleptic-induced catalepsy in mice","volume":"34","author":"Silva","year":"1995","journal-title":"Neuropharmacology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.arr.2014.03.008","article-title":"Alzheimer\u2019s disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes","volume":"15","author":"Silva","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"Psychopharmacology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11096-017-0555-y","article-title":"Efficacy and safety of atypical antipsychotics for behavioral symptoms of dementia among patients residing in long-term care","volume":"40","author":"Sturm","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"B57","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.pnpbp.2012.04.008","article-title":"Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders","volume":"38","author":"Tatara","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2008.09.017","article-title":"Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile","volume":"59","author":"Trifir\u00f2","year":"2009","journal-title":"Pharmacol. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/gps.4037","article-title":"Grouping of behavioural and psychological symptoms of dementia","volume":"29","author":"van der Linde","year":"2014","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B60","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0028-3908(98)00162-2","article-title":"Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat","volume":"38","author":"Wadenberg","year":"1999","journal-title":"Neuropharmacology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1021\/jm010566d","article-title":"Synthesis and pharmacological testing of 1,2,3,4,10,14b\u2013 hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine","volume":"45","author":"Wikstr\u00f6m","year":"2002","journal-title":"J. Med. Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/j.2042-7158.1993.tb07094.x","article-title":"Stereoselective interaction of mianserin with 5-HT3 receptors","volume":"45","author":"Wood","year":"1993","journal-title":"J. Pharm. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.schres.2006.07.010.","article-title":"Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomize, placebo-controlled study","volume":"88","author":"Zhang","year":"2006","journal-title":"Schizophr. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T13:17:54Z","timestamp":1568726274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":63,"alternative-id":["10.3389\/fphar.2019.01045"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01045","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"article-number":"1045"}}